An algorithm for tailoring pharmacotherapy for smoking cessation: Results from a Delphi panel of international experts

Tobacco Control

Volumn 18, Issue 1, 2009, Pages 34-42

  Bader, P ^a,b   McDonald, P ^b,c,d   Selby, P ^b,e,f  

^a Consultants in Behavior Change ^*  (Canada)

^b Ontario Tobacco Research Unit   (Canada)

^c UNIVERSITY OF WATERLOO   (Canada)

^d Population Health Research Group   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BENZAZEPINE DERIVATIVE; NICOTINE; NICOTINIC AGENT; QUINOXALINE DERIVATIVE; VARENICLINE;

ALGORITHM; ARTICLE; BEHAVIOR THERAPY; CLINICAL PRACTICE; CONSENSUS; DECISION SUPPORT SYSTEM; DELPHI STUDY; HUMAN; METHODOLOGY; MULTIMODALITY CANCER THERAPY; SMOKING CESSATION;

ALGORITHMS; BEHAVIOR THERAPY; BENZAZEPINES; BUPROPION; COMBINED MODALITY THERAPY; CONSENSUS; DECISION SUPPORT TECHNIQUES; DELPHI TECHNIQUE; HUMANS; NICOTINE; NICOTINIC AGONISTS; PHYSICIAN'S PRACTICE PATTERNS; QUINOXALINES; SMOKING CESSATION;

EID: 61649123867     PISSN: 09644563     EISSN: 14683318     Source Type: Journal    
DOI: 10.1136/tc.2008.025635     Document Type: Article

References (51)

1. Curry SJ, Sporer AK, Pugach O, et al. Use of tobacco cessation treatments among young adult smokers: 2005 national health interview survey. Am J Public Health 2007;97:1464-9.
2. Rigotti NA. Increasing smoking cessation at the population level: thinking outside the box. J Public Health Management Practice 2006;12:3-5.
3. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: a clinical practice guideline. Rockville, MD: US Department of Health and Human Services, 2000. AHRQ Publication No 00-0032.
4. Le Foll B, Melihan-Cheinin, Rostoker G, et al. Smoking cessation guidelines: evidence-based recommendations of the French health products safety agency. Eur Psychiatry 2005;20:431-41.
5. National Health Committee. Guidelines for smoking cessation. Revised 2002. Wellington: New Zealand Ministry of Health, 2002. Available online: www.nzgg.org.nz. (Accessed 8 March 2008.)
6. Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice. Aust Fam Phys 2002. Special issue.
7. Raw M, McNeill A, West R. Smoking cessation guidelines for health professionals. A guide to effective smoking cessation interventions for the public health system. Thoax 1998;53(suppl5):S1-S38.
8. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 2000;55:987-99.
9. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an a4B2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA 2006;296:47-55.
10. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an a4B2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006;296:56-63.
11. Oncken C, Gonzalez D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist varenicline, for smoking cessation. Arch Intern Med 2006;166:1571- 7.
12. Tonstad SJonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64-71.
13. Kuehn BM. FDA warns of adverse events linked to smoking cessation drug and antileptics. JAMA 2008;299:1121-2.
14. US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General. Rockville, MD: US Government Printing Office, 1990; DHHS Publ No: (CDC) 90-8416.
15. Lamberg L. Patients need more help to quit smoking: counseling and pharmacotherapy double success rate. JAMA 2004;292:1286-90.
16. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004;(3):CD000146.
17. Hughes JR, Shiffman S, Callas P, et al. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control 2003;2:21-7.
18. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007;(4):CD000031.
19. Hey K, Ussher MH, Lancaster T. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation (protocol). Cochrane Database Systeme Rev 2005;(3):CD005353.
20. Comparison of the efficacy and safety of 2 oral doses of Rimonabant, 5 mg/day or 20 mg/day, versus placebo, as an aid to smoking cessation (STRATUS-US). ClinicalTrials.gov identifier: NCT00358228. www.clinicaltrial.gov.
21. Anthenelli R. Rimonabant in smoking abstinence: the STRATUS-program. Society for Research on Nicotine and Tobacco (SNRT) Annual Meeting and 7th Annual European Conference, 20-23 March 2005, Prague, Czech Republic (Presentation).
22. Gourlay SG, Stead LF, Benowitz NL Clonidine for smoking cessation. Cochrane Database Syst Rev 2004;(3):CD000058.
23. Hughes JR, Stead LF, Lancaster T. Anxiolytics for smoking cessation. Cochrane Database Syst Rev 2000;(4):CD002849.
24. Lancaster T, Stead LF. Silver acetate for smoking cessation. Cochrane Database Systeme Rev 1997; (3) :CD000191.
25. Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database Syst Rev 1997;(3):CD000124.
26. Lancaster T, Stead LF. Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane Database Syst Rev 1998;(2):CD001009.
27. Lancaster DS, Stead LF, Evins AE. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev 2006;(4):CD003086.
28. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database System Rev 2008;(3):CD006103.
29. Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2007;103:146-54.
30. Morstad AE, Kutscher EC, Kennedy WK, et al. Hypomania with agitation associated with varenicline use in bipolar Il disorder. Ann Pharmacother 2008;42:288-9.
31. Popkin MK. Exacerbation of recurrent depression as a result of treatment with varenicline. Am J Psychiatry 2008;165:774.
32. Pumariega AJ, Nelson R, Rotenberg L Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr 2008;13:511-4.
33. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007;164:1269.
34. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007;164:1269-70.
35. Hughes JR. Smoking and suicide: a brief overview. Drug Alcohol Depend 2008;Aug 1. Epub ahead of print.
36. Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: US Department of Health and Human Services, 2008. Available at http://www.surgeongeneral.gov/tobacco/ treating-tobacc-use08.pdf.
37. LeFoII BL, George TP. Treatment of tobacco dependence: integrating recent progress into practice. CMAJ 2007;177:1373-80.
38. Croghan IT, Hurt RD, Shaker R, et al. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc 2007;82:186-95.
39. Hughes JR, Goldstein MG, Hurt RD, et al. Recent advances in the pharmacotherapy of smoking. JAMA 1999:281:72-6.
40. Powell C. The Delphi technique: myths and realities. J Adv Nurs 2002;41:37B-82.
41. Jones J, Hunter D. Using the Delphi and nominal group technique in health services research. In: Pope C, Mays N, eds. Qualitative research in health care. 2nd ed. London: BMJ Books, 2000:40-9.
42. Rowe G, Wright G. Expert opinions in forecasting: the role of the Delphi technique. In Armstrong JS, ed. Principles of forecasting. Norwell, MA: Kluwer Academic Publishers, 2000; 125-144.
43. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995;311:376-80.
44. Bader P, Travis H, Skinner HA. Knowledge synthesis of smoking cessation among employed and unemployed young adults. Am J Public Health 2007;97:1434-43.
45. Norman GR, Streiner DL. Biostatistics: the bare essentials. Toronto: Mosby, 1994:179-81.
46. Gorsuch RL. Factor analysis. 2nd ed. Hillsdale, NJ: Laurence Erlbaum, 1983.
47. Selby P. Smoking cessation . In: Gray J, ed. Therapeutic choices, 5th ed. Ottawa, Ontario: Canadian Pharmacist Association, 2007.
48. Hughes J. An algorithm for choosing among smoking cessation treatments. J Subst Abuse Treat 2008;34:426-32.
49. Daar AS, Singer PA, Persad DL, et al. Grand challenges in chronic non-communicable diseases. Nature 2007;450:494-6.
50. Fish LS, Busby DM. The Delphi method. In: DH Sprenkle, ed. Research methods in family therapy. New York: Guilford Press, 1996.
51. Warner KE. Tobacco control policy: from action to evidence and back again. Am J Prev Med 2001;20:2-5.